PMID- 8573552
OWN - NLM
STAT- MEDLINE
DCOM- 19960312
LR  - 20200304
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 9
IP  - 5
DP  - 1995 Oct
TI  - Angiotensin II receptor antagonists in heart failure: rationale and design of the 
      evaluation of losartan in the elderly (ELITE) trial.
PG  - 693-700
AB  - Angiotensin-converting enzyme inhibitors (ACE-I) have been proven to be effective 
      in reducing morbidity and mortality in patients with heart failure or 
      post-myocardial infarction left ventricular dysfunction. Despite evidence from 
      several large-scale randomized trials, the use of ACE-I in patients with heart 
      failure remains relatively low. In part, the failure to achieve more widespread 
      use of ACE-I in patients with heart failure may be due to physician's perceptions 
      of the side effects associated with ACE-I, such as angioedema, renal dysfunction, 
      cough, and hypotension. Many of these side effects are thought to be due to 
      ACE-I-induced bradykinin accumulation. It is possible to inhibit the effect of 
      angiotensin II without increasing bradykinin levels using an angiotensin II type 
      I blocking agent such as losartan. How effective losartan is compared with an 
      ACE-I is uncertain, however. Some of the beneficial effects of ACE-I have been 
      attributed to bradykinin accumulation, and therefore ACE-I might have an 
      advantage compared with an angiotensin II type I receptor antagonist such as 
      losartan. On the other hand, angiotensin II may be produced by 
      non-ACE-I-dependent mechanisms, which would suggest that an angiotensin II type I 
      receptor blocking agent would be advantageous. To determine the relative safety 
      and efficacy of an ACE-I, which results in bradykinin accumulation and inhibitors 
      of angiotensin II, versus an angiotensin II type I receptor blocking agent, which 
      does not result in bradykinin accumulation, we have begun the Evaluation of 
      Losartan In The Elderly (ELITE) trial, which will compare the safety and efficacy 
      of captopril and losartan in elderly patients with heart failure.
FAU - Pitt, B
AU  - Pitt B
AD  - Division of Cardiology, University Hospital, Ann Arbor, MI 48109-0366, USA.
FAU - Chang, P
AU  - Chang P
FAU - Timmermans, P B
AU  - Timmermans PB
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Review
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Imidazoles)
RN  - 0 (Tetrazoles)
RN  - JMS50MPO89 (Losartan)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging/*metabolism
MH  - *Angiotensin Receptor Antagonists
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & 
      dosage/pharmacology/*therapeutic use
MH  - Antihypertensive Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Biphenyl Compounds/administration & dosage/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/metabolism
MH  - Humans
MH  - Imidazoles/administration & dosage/pharmacology/*therapeutic use
MH  - Losartan
MH  - Multicenter Studies as Topic
MH  - Tetrazoles/administration & dosage/pharmacology/*therapeutic use
RF  - 80
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
AID - 10.1007/BF00878552 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 1995 Oct;9(5):693-700. doi: 10.1007/BF00878552.